LB2102在既往接受过多线治疗的实体瘤患者中显示出可控的安全性特征及令人鼓舞的临床活性 在较高剂量水平下,LB2102显示出28.6%的客观缓解率(ORR)和78.6%的疾病控制率(DCR),部分患者获得持久缓解 CARVYKTI®最新数据进一步支持其在多发性骨髓瘤中的持久疗效及一致的安全性特征 美国新泽西州布里奇沃特2026年6月1日 /美通社/ -- 全球细胞疗法领导者传奇生物科技公司(...
Source LinkLB2102在既往接受过多线治疗的实体瘤患者中显示出可控的安全性特征及令人鼓舞的临床活性 在较高剂量水平下,LB2102显示出28.6%的客观缓解率(ORR)和78.6%的疾病控制率(DCR),部分患者获得持久缓解 CARVYKTI®最新数据进一步支持其在多发性骨髓瘤中的持久疗效及一致的安全性特征 美国新泽西州布里奇沃特2026年6月1日 /美通社/ -- 全球细胞疗法领导者传奇生物科技公司(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.